Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening.

[1]  C. Sirlin,et al.  Liver Imaging Reporting and Data System , 2020, Advances in Clinical Radiology.

[2]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[3]  B. Taouli,et al.  Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis , 2017, Clinical and translational gastroenterology.

[4]  P. Kim,et al.  Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium–Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria , 2016, Investigative radiology.

[5]  M. Matsuda.  Clinical value of gadoxetic acid-enhanced magnetic resonance imaging in surgery for hepatocellular carcinoma - with a special emphasis on early hepatocellular carcinoma. , 2015, World journal of hepatology.

[6]  Robert M. Marks,et al.  Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. , 2015, AJR. American journal of roentgenology.

[7]  A. Gamst,et al.  Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma , 2015, Abdominal Radiology.

[8]  U. Motosugi,et al.  Hepatocellular carcinoma risk assessment using gadoxetic acid‐enhanced hepatocyte phase magnetic resonance imaging , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  S. Reeder,et al.  Navigator flip angle optimization for free‐breathing T1‐weighted hepatobiliary phase imaging with gadoxetic acid , 2014, Journal of magnetic resonance imaging : JMRI.

[10]  Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte‐phase image is a risk factor for hypervascular hepatocellular carcinoma , 2014, Journal of magnetic resonance imaging : JMRI.

[11]  H. Hussain,et al.  New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. , 2013, Radiology.

[12]  E. Merkle,et al.  Hepatocellular carcinoma in a North American population: Does hepatobiliary MR imaging with Gd‐EOB‐DTPA improve sensitivity and confidence for diagnosis? , 2013, Journal of magnetic resonance imaging : JMRI.

[13]  Alex Frydrychowicz,et al.  High resolution navigated three‐dimensional T1‐weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 tesla , 2012, Journal of magnetic resonance imaging : JMRI.

[14]  H. Hussain,et al.  Primovist, Eovist: what to expect? , 2012, Journal of hepatology.

[15]  Mustafa R Bashir,et al.  Liver MRI in the hepatocyte phase with gadolinium‐EOB‐DTPA: Does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? , 2012, Journal of magnetic resonance imaging : JMRI.

[16]  Diego R. Martín,et al.  Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. , 2011, Radiology.

[17]  Young Kon Kim,et al.  Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? , 2011, Clinical radiology.

[18]  Cher Heng Tan,et al.  APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review , 2011, International journal of hepatology.

[19]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[20]  D. Lu,et al.  CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  E. Merkle,et al.  Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging , 2011, European Radiology.

[22]  C. Catalano,et al.  Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. , 2010, Radiology.

[23]  Paul Nikolaidis,et al.  Utility of diffusion‐weighted MRI in distinguishing benign and malignant hepatic lesions , 2010, Journal of magnetic resonance imaging : JMRI.

[24]  M. Kudo,et al.  Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009) , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  J. Marrero,et al.  Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[26]  E. Hatano,et al.  Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma , 2009, Journal of Gastroenterology.

[27]  Howard Y. Chang,et al.  Decoding global gene expression programs in liver cancer by noninvasive imaging , 2007, Nature Biotechnology.

[28]  G. Casazza,et al.  Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review , 2006, The American Journal of Gastroenterology.

[29]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[30]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[31]  L. Bolondi.  Screening for hepatocellular carcinoma in cirrhosis. , 2003, Journal of hepatology.

[32]  G. Krinsky,et al.  Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. , 2002, AJR. American journal of roentgenology.